The interstices of the mammalian stratum corneum contain lipids in a system of continuous membrane bilayers critical for the epidermal permeability barrier. During the transition from inner to outer stratum corneum, the content of polar lipids, including glucosylceramides, decreases while ceramide content increases. We investigated whether inhibition of glucosylceramide hydrolysis would alter epidermal permeability barrier function. Daily topical applications of bromoconduritol B epoxide (BrCBE) to intact murine skin selectively inhibited fl-glucocerebrosidase, increased glucosylceramide content of stratum corneum with ceramide content remaining largely unchanged, and caused a progressive, reversible decrease in barrier function. Histochemistry of inhibitor-treated epidermis revealed persistence of periodic acid-Schiff-positive staining in stratum corneum cell membranes, consistent with retention of hexose moieties. Electron microscopy of inhibitor-treated samples revealed no evidence of toxicity or changes in the epidermal lipid delivery system. However, immature membrane structures persisted in the intercellular spaces throughout the stratum corneum, with reappearance of mature membrane structures progressing outward from the lower stratum corneum upon termination of BrCBE. Finally, the induced barrier abnormality was not reversed by coapplications of ceramide. These data demonstrate that glucosylceramide hydrolysis is important in the formation of the epidermal permeability barrier, and suggest that accumulation of glucosylceramides in stratum corneum intercellular membrane domains leads to abnormal barrier function. (J. Clin. Invest. 1993.91:1656-1664 
Introduction
Sphingolipids are important components of the mammalian permeability barrier (1) (2) (3) , and their synthesis in the epidermis is critical for barrier maintenance (4, 5) . In addition to accumulation of sphingolipids during the final stages of stratum corneum differentiation, other marked changes in lipid composition occur, the importance of which are not well understood. A general elimination of polar lipids, including glucosyl- ( 10, 11 ) have been localized to the sites where these transformations occur. Moreover, many of these enzymes have been colocalized with the epidermal lamellar body ( 12, 13) , which is the delivery mechanism for most of these enzymes and their lipid substrates to the stratum corneum (reviewed in reference 14) . Secretion of lamellar body contents results in the segregation oflipids and hydrolytic enzymes to the intercellular spaces of the stratum corneum (7, 8, 12) . Subsequently, a series of transformations in membrane structure occur, resulting in the formation of the basic lamellar membrane unit characteristic of the stratum corneum of terrestrial mammals ( 15, 16) .
In addition to the biochemical and structural gradients described above, other circumstantial evidence suggests that the conversion of GlcCer to ceramide may be important for the maintenance of optimum barrier function. In both mucosal epithelia ( 17) , and in the epidermis of marine cetaceans ( 18) , both ofwhich have less competent barriers than epidermis, the ratio of glucosylceramides to ceramides remains high. Moreover, fl-glucosidase levels are lower in oral mucosa than in the epidermis of the same species ( 19) . Whereas fl-glucosidase activity has been quantitated previously in a number of epidermal preparations (20) (21) (22) (23) (24) (25) (26) (27) , we recently demonstrated that the bulk ofthis activity is fl-glucocerebrosidase (f3-GlcCer'ase) and that it is localized largely to the outer epidermis and stratum corneum ( 1 1) . Although these prior studies suggest that extracellular processing ofglycosphingolipids may be important for the development of barrier integrity, proof of this hypothesis has been lacking.
In order to directly test the hypothesis that extracellular sphingolipid processing is necessary for barrier maintenance, we applied an inhibitor of f3-GlcCer'ase, bromoconduritol B epoxide (BrCBE; [28] [29] [30] , topically to intact skin, and found that this agent caused a progressive, reversible alteration in barrier integrity. Abnormal barrier function was associated with enzyme inhibition, enhanced sphingolipid synthesis, and accumulation of GlcCer in the stratum corneum. Moreover, these biochemical changes were accompanied by persistence of immature membrane structures in the stratum corneum. These results strongly support the hypothesis that extracellular 1 . Abbreviations used in this paper: BrCBE, bromoconduritol B epoxide ( 1,2-anhydro-6-bromo-6-deoxy-myo-inositol); CBE, conduritol-B epoxide (1,2-anhydro-myo-inositol); dNJM, deoxynojirimycin; GlcCer, glucosylceramide; fl-GlcCer'ase, fl-glucocerebrosidase; HPTLC, high performance thin layer chromatography; 4 Animals. Hairless male mice (Hr/Hr) were purchased from Simonsen Laboratories (Gilroy, CA), and fed Purina mouse diet and water ad libitum. All animals were eight-12 weeks old at the time of study. Barrier function was assessed as transepidermal water loss (TEWL), and was measured at various time points with an electrolytic water analyzer (Meeco, Warrington, PA), as described in detail previously (4, 5, 33) . Water loss measurements are obtained over a small area ofskin (0.5 cm2), recorded in parts per million/0.5 cm2 per h over background. At each timepoint, three to five readings are performed on each flank (both treated and untreated), with six to eight animals in each test group.
Preparation ofepidermal homogenates. Epidermal sheets were obtained from hairless mice by first removing whole skin samples from authorized animals and exposing samples to dry heat (60'C, 60 s), followed by gentle scraping with a scalpel blade. All subsequent steps were performed at 4VC, unless otherwise noted. Epidermal sheets were homogenized in 10 vol of PBS (with 0.1 mM PMSF) using a Polytron (15 s, x3 bursts), and sonication (35%, 10 s X 2 bursts). Protein concentrations were measured using the Bradford procedure (34) with bovine serum albumin (BSA) serving as the standard.
Preparation ofstratum corneum. Epidermal sheets first were separated from dermis by soaking in calcium/magnesium-free Dulbecco's phosphate-buffered saline solution (PBS-CMF), containing 10 mM EDTA for 1.0 h at 37°C. Epidermal sheets then were floated for 1.0 h at 25°C in 0.5% trypsin solution (in PBS-CMF), at which point the trypsin solution was changed. After 30 min the tissue was gently sonicated for 10 min and rinsed with distilled water, and each sheet of stratum corneum was trimmed to the same size (= 19 X 25 mm).
Epidermal f3-glucosidase assay. Our assay methods for ,B-glucosidases are modified from that of Mier and van den Hurk (35) , as reported previously ( 11) . Briefly, assays were performed at 37°C in citrate-phosphate buffer (pH 5.6) containing 5 mM (0.54%) sodium taurocholate, with 0.5 mM 4MU-1-D-glucoside as substrate, and a 60-min reaction time. Enzyme solutions in assay buffer (50 Ml) were preheated in siliconized glass culture tubes, and reactions initiated by the addition of 50 g I of substrate solution in assay buffer. Reactions were terminated by adding 1.25 ml of200 mM carbonate-bicarbonate buffer (pH 10.5). The fluorescence (ex = 360 rm, em = 450 rm) was measured with a fluorescence spectrophotometer (Perkin-Elmer Corp., Norwalk, CT; model 204). A standard 4MU solution (0-300 nM) in carbonate-bicarbonate buffer was used for calibration of each assay.
Inhibition off3-GIcCer'ase activity. The inhibition of fl-GlcCer'ase was first determined for each of four inhibitors (CBE, BrCBE, bromoconduritol, and dNJM; see Fig. 1 ) in vitro using epidermal extracts. Inhibitors were preincubated with enzyme for 15 min (37°C) before assay mitigation by substrate addition. Inhibitor concentrations in the assay mixture were varied from 10-9 to 10 2M and estimates ofappar-then tested by determining the effects ofBrCBE on the activity ofother glucosidases. First, the pH dependence (20 mCi/0.2 ml) administered 1 h after either BrCBE treatment or vehicle application. 2 h after the injection, blood samples were taken and the animals were killed. Whole skin was excised (-8 cm2) from each flank (BrCBE-treated and -untreated sides), heated for 60 s (60°C), and the epidermis was separated from the dermis with gentle scraping, as described above. Samples were blotted dry, weighed, minced, and immediately placed into screw-cap glass test-tubes containing BlighDyer solvents, and total lipid extracts were prepared, as described above. The lipid components were separated by HPTLC, as described previously (4, 5) , visualized using fluorescence to UV-A light after 8-anilino-1-naphthalene-sulfonic acid staining (2), identified by cochromatography with known standards, scraped into scintillation vials, and counted by liquid scintillation spectrometry. Incorporation of tritium into total ceramide and glucosylceramide fractions was determined. Using the specific activity of 3H-H20 in serum samples from each animal, results were presented as ,moles product formed/mg of epidermal wet weight over the 2 hr. incubation, as described previously (4, 5, 38, 39) .
Histochemistry. Fresh, full-thickness skin samples were obtained before treatment, and at various time points after daily applications of BrCBE and vehicle. Samples were fixed in buffered formalin, paraffinembedded, and sectioned (5 Am). Parallel sections were stained with periodic acid-Schiff, hematoxylin/eosin, and colloidal iron. Sections then were examined and photographed with a Leitz Ortholux II microscope.
Transmission electron microscopy. At various time points following treatment with the protocols described above, full-thickness skin biopsies were obtained from euthanized animals, minced to < 0.5 mm2, and fixed in modified Karnovsky's fixative overnight. Samples then were postfixed in both 0.2% ruthenium tetroxide, utilizing a recently described protocol ( 16) , and 2% aqueous osmium tetroxide, both containing 1.5% potassium ferrocyanide in the dark. After fixation, all samples were dehydrated in graded ethanol solutions, and embedded in an Epon-epoxy mixture (40 
Results
Effect ofBrCBE on epidermal f-glucosidase activity To address the biochemical basis for the effects ofBrCBE in the epidermis, we first determined the inhibition of f3-glucocerebrosidase activity by BrCBE and its chemically related and unrelated analogues (Fig. 1) (Fig. 2) . The 50-fold lower value for BrCBE is consistent with published results (29) . Moreover, a single topical application of BrCBE to intact murine epidermis resulted in a dose-and time-dependent inhibition of j-glucosidase activity. A dose of 375 Mmol/5 cm2 resulted in over 90% inhibition at 1 h, with activity recovering to 50% of control by 24 hours (Table I) . Consistent with their IC50 values, single topical applications ofequimolar doses ofCBE, bromoconduritol, and dNJM resulted in less inhibition ofepidermal fl-glucosidase activity (40, 41 ; and 0% at 1 h, respectively). These enzymatic studies demonstrate significant inhibition of epidermal f3-glucosidase by a single topical application of BrCBE.
The specificity of BrCBE for j-glucosidase over other glucosidases then was determined in epidermal homogenates. Assays were performed with and without added BrCBE using the (Fig. 3) .
Effect of repeated topical applications ofBrCBE on epidermal barrier function We next investigated whether chronic inhibition of f3-glucosidase would alter epidermal barrier function. Daily applications of BrCBE to intact murine epidermis resulted in progressive disruption ofthe epidermal permeability barrier reaching maximal levels by five to seven days, and plateauing thereafter (Fig.  4) . Although the levels ofwater loss were moderately increased (TEWL < 0.6± 1.0 mg/cm2 per h), they are nearly 10-fold less than produced by physical and chemical forms of barrier disruption, such as acetone-extraction or tape-stripping (33) . Cessation of topical BrCBE led to a gradual normalization of TEWL rates over 5 d, with the majority ofimprovement occurring within the first 48 h (Fig. 4) Structural alterations induced by BrCBE treatment As described previously (41 ), the stratum corneum membrane domains in control epidermal samples do not stain positively for glycoconjugates with either periodic acid-Schiff for neutral hexose residues, or colloidal iron for acidic polysaccharide residues. In contrast, in samples treated with BrCBE for five days, the stratum corneum displayed increased PAS staining intensity while the colloidal iron staining ofthe epidermis remained unchanged relative to control samples (data not shown). These histochemical results are consistent with increased glucosylceramide content in the stratum corneum. In order to ascertain the subcellular basis for the BrCBE effect on permeability barrier function, we next examined control vs. inhibitor-treated epidermis by electron microscopy ( Figs. 7 and 8) . In samples treated for three days with BrCBE, at a time when barrier function is still largely intact (c.f., Fig.  4 ), a striking abnormality in lamellar bilayer unit structures first became apparent in the lower stratum corneum. Elongated lamellar body-derived sheets (Fig. 7 B) , with the same substructure and dimensions as initially secreted lamellar body pleated sheets (42) , replaced the normal membrane unit structure (Fig. 8 A) . In contrast, lamellae in the outer layers still displayed the normal mature unit structure (Fig. 7 A) . In samples treated for seven successive days with BrCBE, there was no evidence of cytotoxicity; i.e., nuclei, mitochondria, and other organelles appeared unaffected (not shown). Moreover, the internal structure ofepidermal lamellar bodies (Fig. 7 D, interface (Fig. 7 D) . In contrast to the 3-d samples, however, the abnormality in lamellar bilayer unit structure was now evident in the intercellular spaces at all levels of the stratum corneum (Fig. 7 C) . Moreover, these elongated, unprocessed sheets were loosely packed and often separated by clefts; i.e., nonlamellar domains (Fig. 7 C, asterisks) . Finally, when treated animals are allowed to revert by cessation of topical inhibitor applications for two days, the membrane abnormali- Br ties initially persist in the mid-to-outer stratum corneum, while newly formed, mature, lamellar basic unit structures appear in the lower stratum corneum (Fig. 8 A) . By 6 d after cessation of treatment, the mature lamellar unit structure is evident throughout the stratum corneum (Fig. 8 B) . These (8, 42) .
The present study provides the first direct evidence that the conversion of glucosylceramides to ceramides is a prerequisite for the maintenance of a competent permeability barrier in a terrestrial environment. Repeated topical applications of BrCBE, a potent inhibitor of B-GlcCer'ase (28) (29) (30) , to intact Br-CBE Figure 5 . Effect of BrCBE on [3H]-H20 incorporation into sphingolipids. 1 h after topical treatment with either vehicle (control) or BrCBE, [3H]-H20 was injected intraperitoneally. 2 h later, epidermis was isolated, lipids were extracted and radioactivity quantitated (see Methods). Data are presented as the mean incorporation of tritium over 2 hrs. from triplicate determinations (±SD). Whereas, increased glucosyl-ceramide synthesis was observed in BrCBE-treated epidermis (P < 0.05 vs. vehicle-treated controls), incorporation into ceramides remained unchanged.
sion of the barrier abnormality correlates with replacement of mature membrane structures by incompletely processed "immature" lamellae at all levels of the stratum corneum interstices.
Discussion
The formation of the stratum corneum in the epidermis of terrestrial mammals is accompanied by striking changes in lipid composition and distribution (reviewed in references 14 and 43). During the final stages of this differentiation process, a lipid mixture enriched in ceramides, cholesterol, and free fatty acids replaces the phospholipid-neutral lipid mixture present in the subjacent nucleated layers ( 1, 2, 6 ). Moreover, these lipids become segregated within intercellular domains at the level ofthe stratum corneum ( 14) . These changes in lipid composition can be attributed to two distinct cellular process. The first involves active de novo synthesis, which is sustained into the outer nucleated cell layer, the stratum granulosum (44) (45) (46) . Much of the newly synthesized sphingolipids and cholesterol are packaged in epidermal lamellar bodies, organelles enriched in these lipid species ( 12, 13) , which provide the secretory mechanism for delivery of these lipids to the stratum corneum interstices (reviewed in reference 14). However, the lamellar body is not enriched in ceramides and free fatty acids, but rather in glycosphingolipids and phospholipids (12, 13) . Thus, the second process results in the conversion ofthe glycosphingolipid-cholesterol-phospholipid mixture to the ceramide-cholesterol-free fatty acid mixture which emerges within the stratum corneum. This conversion is presumed to result from hydrolysis by a family of lipases and glycosidases that are co-packaged with lipids in the lamellar body (7, 8, 12, 13) . Moreover, the co-deposition of lamellar body lipids and enzymes appears to be followed not only by the biochemical changes noted above, but also by parallel modulations in memmurine skin were accompanied by a progressive increase in TEWL, which plateaued after several days. Interestingly, chemically related and unrelated compounds (CBE, bromoconduritol, and dNJM) inhibited f3-glucosidase activity, but to a lesser degree. Chronic treatment with these compounds affected neither the sphingolipid distribution within the epidermis nor permeability barrier function. Thus, it is likely that the remaining epidermal enzyme activity ( -60% at 1 h after treatment) was sufficient to allow ongoing hydrolysis ofglucosylceramide. Similar findings were reported during the development of an animal model for Gaucher's disease, where glucosylceramide accumulation was observed only when inhibition of 3-GlcCer'ase activity was maintained below 12-16% of control values (47) .
Moreover, patients with decreased f3-GlcCer'ase activity, do not demonstrate Gauchers disease symptoms unless activity is less than -20% of normal. Heterozygous patients, despite lower than normal enzyme activity, do not show evidence of disease.
The barrier abnormality induced by BrCBE is likely caused by increased glucosylceramide secondary to inhibition of (3- glucocerebrosidase and not due to nonspecific toxicity because: First, BrCBE did not inhibit other closely related glucosidases, suggesting that the barrier abnormality is attributable to a selective inhibition of GlcCer'ase. Second, BrCBE treatment resulted in an accelerated, rather than a depressed incorporation of [3H]H20 into glucosylceramide, with the increase in stratum corneum GlcCer content reflecting an inhibition ofhydrolysis. Third, the effects ofBrCBE on epidermal barrier function were reversible upon cessation of treatment. Fourth, chemi- pensatory mechanisms for increasing the ceramide content of the stratum corneum are operative during BrCBE treatment, possibly through sphingomyelin hydrolysis, is currently under investigation.
The structural studies also provided insights into the mechanism whereby glucosylceramide accumulation induces the barrier abnormality. The intercellular bilayers in BrCBEtreated samples revealed elongated lamellar body sheets in parallel, loosely packed arrays, but no mature, lamellar basic membrane unit structures. The barrier abnormality appears to peak and plateau at a point when these immature membrane structures replace the basic membrane unit structures at all levels of the stratum corneum. Mature lamellar unit structures are characteristic of epidermis which exhibits an intact barrier, and they are replaced by immature structures both in occluded skin (42) , and in the epidermis of marine cetaceans ( 18) . It is noteworthy that in each of these situations, barrier requirements are far less stringent than in the terrestrial, air-exposed environment. Pertinently, glucosidase levels also are reportedly low in mucosal epithelia ( 19) , and glucosylceramides accumulate in both mucosal epithelia (17) and cetacean epidermis ( 18) . All of these data support the direct evidence presented here that extracellular glucosylceramide processing to ceramides is required for epidermal barrier competence in terrestrial mammals.
In summary, we have shown that the hydrolysis ofglucosylceramides to ceramides is a requirement for epidermal permeability barrier function in terrestrial mammals. Topical applications of bromoconduritol B epoxide to intact skin inhibited f3-glucocerebrosidase activity, accompanied by accelerated synthesis and accumulation ofglucosylceramides in the epidermis. These biochemical changes were associated with the persistence of immature, lamellar body-derived membrane structures within the intercellular spaces of the stratum corneum.
cally-related chemicals which are less potent inhibitors of fBglucosidase, did not alter glucosylceramide content or produce an abnormality in barrier function. Fifth and finally, histochemical and ultrastructural studies revealed no evidence of inflammation or cytotoxicity in inhibitor-treated tissues. Since the ,B-glucosidase activity of the epidermis is primarily fiGlcCer'ase ( 1 1), the barrier abnormality appears to stem from specific inhibition of this enzyme.
The inhibition of fp-GlcCer'ase could produce the barrier defect by two distinct biochemical mechanisms; i.e., through a decrease in ceramide generation from glucosylceramides or through an accumulation of glucosylceramides. Our studies clearly point to the latter mechanism as the principle cause of the barrier abnormality. Whereas 
